Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Down 0.8% - Here's Why

Key Points

• Bayer shares fell 0.8% to $12.30 in Friday trading, with volume slightly below the stock’s average session volume.
• Analyst sentiment improved, with Zacks Research upgrading Bayer to “strong buy” and Deutsche Bank upgrading it to “buy.” Overall, analysts maintain an average “Buy” rating.
• Bayer exceeded quarterly expectations, reporting EPS of $0.29 versus the $0.23 consensus and revenue of $12.53 billion versus $12.31 billion expected. The company reaffirmed fiscal 2026 EPS guidance of $1.20–$1.346.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report)'s stock price traded down 0.8% on Friday. The company traded as low as $12.11 and last traded at $12.30. Approximately 553,484 shares were traded during trading, a decline of 7% from the average session volume of 597,667 shares. The stock had previously closed at $12.40.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a research note on Friday, July 10th. Deutsche Bank Aktiengesellschaft upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Thursday, July 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Buy".

Bayer Aktiengesellschaft Trading Down 0.8%

The business's 50-day moving average is $13.53 and its two-hundred day moving average is $12.63. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.67 and a current ratio of 1.04. The stock has a market capitalization of $48.34 billion, a PE ratio of -24.12, a price-to-earnings-growth ratio of 1.88 and a beta of 0.57.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.29 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.06. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 16.77%. The company had revenue of $12.53 billion during the quarter, compared to the consensus estimate of $12.31 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, equities research analysts anticipate that Bayer Aktiengesellschaft will post 1.27 earnings per share for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a Germany-based life sciences company headquartered in Leverkusen. Founded in 1863 by Friedrich Bayer and Johann Friedrich Weskott, the company develops products in health care and agriculture and serves customers in markets around the world.

Bayer operates through three primary businesses: Pharmaceuticals, Consumer Health and Crop Science. Its Pharmaceuticals segment develops prescription medicines in areas such as cardiovascular disease, women's health, oncology, hematology and specialty therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.